A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.

Trial Details

NCT ID
NCT07312188
Phase
PHASE2
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • F182112+P
  • F182112+CD38
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Be diagnosed with multiple myeloma according to the IMWG 2016 criteria.
  • The previous treatment regimen must contain lenalidomide (lenalidomide must be used continuously for at least 2 cycles) and a proteasome inhibitor.
  • Participants whose previous treatment regimen contained pomalidomide or who were intolerant to pomalidomide cannot be enrolled.
  • Have an ECOG performance status score of 0 - 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →